A randomised, crossover trial exploring the patient perspective and effectiveness of biosimilar adalimumab transition: IBD reference and biosimilar adalimumab cross over study (iBaSS)-Reference-Cited by-同舟云学术

A randomised, crossover trial exploring the patient perspective and effectiveness of biosimilar adalimumab transition: IBD reference and biosimilar adalimumab cross over study (iBaSS)

Published:2024-05-11 Issue:5 Volume:46 Page:1091-1101
ISSN:2210-7703
Container-title:International Journal of Clinical Pharmacy
language:en
Short-container-title:Int J Clin Pharm

Author:

Young David^ORCID,Harris Clare^ORCID,Rahmany Sohail^ORCID,Iria Inês,Gonçalves João,Addison Janet,Harvey Justin,Latter Sue^ORCID,Cummings Fraser^ORCID

Funder

Biogen Idec Ltd.

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11096-024-01739-5.pdf

Reference25 articles.

1. Peyrin-Biroulet L, Panés J, Sandborn WJ, et al. Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol. 2016;14(3):348-354.e17. https://doi.org/10.1016/j.cgh.2015.06.001.

2. Berg DR, Colombel JF, Ungaro R. The role of early biologic therapy in inflammatory bowel disease. Inflamm Bowel Dis. 2019;25(12):1896–905. https://doi.org/10.1093/ibd/izz059.

3. Burisch J, Vardi H, Schwartz D, et al. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. Lancet Gastroenterol Hepatol. 2020;5(5):454–64. https://doi.org/10.1016/S2468-1253(20)30012-1.

4. D’Haens GR, Van Deventer S. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. Gut. 2021;70(7):1396–405. https://doi.org/10.1136/gutjnl-2019-320022.

5. Committee for Medicinal Products for Human Use. Guideline on Similar Biological Medicinal Products. European Medicines Agency; 2014. Accessed 01 Sep 2021. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf.